Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper Fernando BarataCarlos AguiarVenceslau Hespanhol Current Opinion 03 June 2021 Pages: 825 - 834
The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology Vicki OsborneSamantha LaneSaad A. W. Shakir Leading Article Open access 07 May 2021 Pages: 835 - 841
Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities Veronique F. KugenerEric S. FreedlandMaxine Gossell-Williams Leading Article 15 May 2021 Pages: 843 - 852
Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders Carla J. JonkerSieta T. de VriesPeter G. M. Mol Original Research Article Open access 06 June 2021 Pages: 853 - 861
Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study Xuerong WenOluwadolapo D. LawalKimford J. Meador Original Research Article 07 June 2021 Pages: 863 - 875
Prevalence, Nature, Severity and Preventability of Adverse Drug Events in Mental Health Settings: Findings from the MedicAtion relateD harm in mEntal health hospitals (MADE) Study Ghadah H. AlshehriDarren M. AshcroftRichard N. Keers Original Research Article 05 July 2021 Pages: 877 - 888
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019 Juliana SetyawanNassir AzimiMoshe Fridman Original Research Article Open access 13 June 2021 Pages: 889 - 897
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Veena HoffmanJesper Hallasthe mirabegron PMR-PASS study group Original Research Article Open access 08 July 2021 Pages: 899 - 915